Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease

Clinical and Translational Science

Volumn 7, Issue 5, 2014, Pages 384-390

  Krajnović, Milena ^a   Jovanović, Maja Peruničić ^b   Mihaljević, Biljana ^b,c   Andelić, Boško ^b   Tarabar, Olivera ^d   Knežević Ušaj, Slavica ^e   Krtolica, Koviljka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF DEFENCE   (Serbia)

^e UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Diffuse large B cell lymphoma; Methylation; p15; Prognosis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DAPK1 PROTEIN, HUMAN; DEATH ASSOCIATED PROTEIN KINASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; MONOCLONAL ANTIBODY; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DAPK GENE; DNA METHYLATION; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MGMT GENE; OVERALL SURVIVAL; P15 GENE; P16 GENE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VERY ELDERLY; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PATHOLOGY; SURVIVAL; TUMOR INVASION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEATH-ASSOCIATED PROTEIN KINASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84911367433     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12162     Document Type: Article

References (45)

1. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietics and Lymphoid Tissues IARC Press, Lyon, 2001, pp, 171-174.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994.
3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998; 16: 2780-2795.
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-511.
5. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002; 346: 1937-1947.
6. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005; 87: 163-208.
7. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphomatreated with R-CHOP. Blood. 2007; 109: 1857-1861.
8. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349: 2042-2054.
9. Martinez-Delgado B, Robledo M, Arranz E, Osorio A, Garcia MJ, Echezarreta G, Rivas C, Benitez J. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphoma. Leukemia. 1998; 12: 937-941.
10. Baur AS, Shaw P, Burri N, Delacrétaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15 INK4b (MTS2) and p16 INK4a (MTS1) in B-cell and T-cell lymphomas. Blood. 1999; 94: 1773-1781.
11. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, et al. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 2004; 89: 154-164.
12. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, et al. Hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002; 94: 26-32.
13. Shiozawa E, Takimoto M, Makino R, Adachi D, Saito B, Yamochi-Oniyuka T, Yamochi T, Shimozuma J, Maeda T, Kohno Y, et al. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res. 2006; 30: 859-867.
14. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 2008; 19: 1774-1786.
15. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000; 462: 83-100.
16. Ng MH. Death associated protein kinase: from regulation of apoptosis to tumor suppresive function and B cell malignancies. Apoptosis. 2002; 7: 261-270.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244-1253.
18. Krtolica K, Krajnović M, Ušaj-Knežević S, Babić D, Jovanović D, Dimitrijević B. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol. 2007; 13: 1187-1194.
19. Sambrook J, Fritsch EF, Maniatis T. Analysis and cloning of eukariotic genomic DNA. In: Ford N, Nolan C, Ferguson M, eds. Molecular Cloning. A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press; 1989, pp, 16-19.
20. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996; 93: 9821-9826.
21. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59: 793-797.
22. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999; 93: 4347-4353.
23. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998; 12: 845-859.
24. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's lymphoma and CD30-positive non-Hodgkin lymphomas. Am J Pathol. 2002; 161: 1007-1013.
25. Sanchez-Beato M, Saez AI, Navas IC, Algara P, Sol Mateo M, Villuendas R, Camacho F, Sanchez-Aguilera A, Sanchez E, Piris MA. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol. 2001; 159: 205-213.
26. Lee SM, Lee EJ, Ko YH, Lee SH, Maeng L, Kim KM. Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphoma. APMIS. 2009; 117: 87-94.
27. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010; 116: 1092-1104.
28. INK4a promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. Leuk Res. 2011; 35: 438-443.
29. Peruničić Jovanović M, Jaković Lj, Bogdanović A, Marković O, Čemerikić V, Mihaljevićć B. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells. Vojnosanit Pregl. 2009; 66: 738-743.
30. Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Feiden W, Steudel WI, Rahnenführer J, Urbschat S. p15 promoter methylation - a novel prognostic marker in glioblastoma patients. Int Journal Oncol. 2009; 34: 1743-1748.
31. Deneberg S, Grovdal M, Karimi M, Jansson M, Nahi H, Corbaciogly A, Gaidzik V, Dohner K, Paul C, Ekstrom TJ, et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia. 2010; 24: 932-941.
32. Kim M, Oh B, Kim SY, Park HK, Hwang SM, Kim TY, She CJ, Yang I, Yoon SS, Yoon JH, et al. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndrome in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res. 2010; 34: 718-722.
33. El-Maarri O, Becker T, Junen J, Manzoor SS, Diaz-Lacava A, Schwaab R, Wienker T, Oldenburg J. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet. 2007; 122: 505-514.
34. Muller C, Murawski N, Wiesen MHJ, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, et al. The role of gender and weight on rituximab clearance and serum elimination half life in elderly patients with DLBCL. Blood. 2012; 119: 3276-3284.
35. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S, Seto M. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005; 106: 1770-1777.
36. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008; 105: 13520-13525.
37. Guney S, Jardin F, Bertrand P, Mareschal S, Parmentier F, Picquenot JM, Tilly H, Bastard C. Several mechanisms lead to the inactivation of the CDKN2A (p16), p14ARF, or CDKN2B (p15) genes in the GCB and ABC molecular DLBCL subtypes. Genes Chromosomes Cancer. 2012; 51: 858-867.
38. Cameron EE, Baylin BS, Herman JG. p15 (INK4B) CpG island methylation in primary acute leukemia is heterogenous and suggests density as a critical factor for trancriptional silencing. Blood. 1999; 94: 2445-2451.
39. Gronbaek K, deNully Brown P, Moller MB, Nedergaard T, Ralfkiaer E, Moller P, Zeuthen J, Guldberg P. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia. 2000; 14: 1727-1735.
40. Kraguljac N, Krajnović M, Dimitrijević B, Mihaljević B, Gotić M, Krtolica K. Frequency of aberrant promoter methylation of p15INK4B and O6-methylguanine-DNA methyltransferase genes in B-cell non-Hodgkin lymphoma: a pilot study. Arch Biol Sci. 2010; 62: 211-221.
41. Kim SS, Choi YH, Han CW, Choi YD, Park Y, Lee JJ, Kim HJ, Lee IK, Lee JS, Juhng SW, et al. DNA methylation profiles of MGMT, DAPK1, bhMLH1, CDH1, SHP1, and HIC1 in B-cell lymphomas. Korean J Pathol. 2009; 43: 420-427.
42. 6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? Leuk Lymphoma. 2009; 50: 1992-1998.
43. Voso MT, Gumiero D, D'Alo' F, Guidi F, Mansueto G, Di Febo AL, Massini G, Martini M, Larocca LM, Hohaus S, et al. DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica. 2006; 91: 1252-1256.
44. Cohen O, Kimchi A. DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ. 2001; 8: 6-15.
45. Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Knamaru A, Ogawa H, Aozasa K. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol. 2007; 86: 557-564.